A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Public ClinicalTrials.gov record NCT06045806. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).
Study identification
- NCT ID
- NCT06045806
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 79 participants
Conditions and interventions
Conditions
Interventions
- idecabtagene vicleucel Biological
- Lenalidomide Drug
- Fludarabine Drug
- Cyclophosphamide Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 16, 2023 (Actual)
- Primary completion
- Aug 11, 2025 (Actual)
- Completion
- Nov 20, 2029 (Estimated)
- Last update posted
- Mar 5, 2026
2023 – 2029
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0131 | Los Angeles | California | 90095 | — |
| Local Institution - 0126 | Orange | California | 92868 | — |
| Local Institution - 0113 | Sacramento | California | 95817 | — |
| Colorado Blood Cancer Institute | Denver | Colorado | 80218 | — |
| Yale University School of Medicine | New Haven | Connecticut | 06510 | — |
| AdventHealth Orlando | Orlando | Florida | 32804 | — |
| Local Institution - 0121 | Atlanta | Georgia | 30322 | — |
| Local Institution - 0104 | Atlanta | Georgia | 30342 | — |
| Local Institution - 0151 | Boston | Massachusetts | 02215 | — |
| Ascension Providence Hospital | Southfield | Michigan | 48075 | — |
| M Health Fairview Clinics and Surgery Center | Minneapolis | Minnesota | 55455 | — |
| Washington University School of Medicine | St Louis | Missouri | 63108 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Columbia University Irving Medical Center | New York | New York | 10032 | — |
| Novant Health Cancer Institute - Elizabeth | Charlotte | North Carolina | 28204 | — |
| The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| Local Institution - 0132 | Philadelphia | Pennsylvania | 19104 | — |
| Local Institution - 0124 | Austin | Texas | 78704 | — |
| Local Institution - 0109 | Houston | Texas | 77030 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 81 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06045806, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 5, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06045806 live on ClinicalTrials.gov.